Caspr — Sodium Production for Pharma

CASPR

Intelligence Report

Intelligence · Analytical AI

Sodium
Production
for Pharma

An analysis of India's pharmaceutical sodium market: supply concentration, production economics, and capital viability.

Intelligence

2024

146

pages · fully cited
delivered in under 15 min

01

India imports 75% of pharmaceutical sodium — a structural dependency with no near-term domestic substitute

7,500 tonnes/year · China: sole credible source · No WHO-GMP certified domestic producer

This analysis supports a go/no-go decision on greenfield pharmaceutical-grade sodium production in India, and identifies the three variables that determine investment viability.

Finding 1 — Supply concentration risk is acute

India sources 75% of pharmaceutical-grade sodium from China. A 15% tariff event pushes prices above USD 4.20/kg — eliminating margin for most manufacturers. No domestic substitute within 24 months.

75%

China import share

Finding 2 — Production economics are marginal at small scale

Below 6,000 tonnes annual output, no scenario produces an IRR above cost of capital. Minimum viable greenfield: INR 280 crore. Incremental entry is not rational.

INR
280Cr

min viable capex

Finding 3 — Regulatory timeline is the critical path

CDSCO approval as an API precursor adds 18–24 months before commissioning. Any capital deployment decision must price in this lead time.

22mo

CDSCO critical path

The data narrows the decision to scale and timing. Below 6,000 tonnes, the economics do not justify greenfield capital at current import pricing.

SECTION 1.1 · IMPORT VOLUME AND SOURCES Page 7

TABLE 1.1

China dominates: 75% of India's pharmaceutical sodium imports, 2024

Source Country	Volume (T/yr)	Market Share	Avg Price USD/kg	Lead Time (weeks)
China	5,625	75.0%	2.67	14–18
Germany	750	10.0%	4.15	6–8
USA	525	7.0%	4.42	8–10
Netherlands	375	5.0%	4.28	6–8
Other	225	3.0%	3.90	varies
Total / Market avg	7,500	100%	2.97	—

Source: Ministry of Chemicals and Fertilizers, India; DGCI&S import data 2024. Caspr analysis.

China-origin supply undercuts all alternatives by 36–65%. At USD 2.67/kg, no other source is competitive at scale — and no domestic producer holds WHO-GMP certification.

A 15% tariff event on China-origin imports would push effective landed cost to approximately USD 3.07/kg — still below European alternatives, but sufficient to erode finished goods margin by 8–12% for most manufacturers. The market has no near-term substitute.

USD
2.67 China avg price/kg — 36% below next-cheapest source

Import Volume and Sources 7

Caspr

SECTION 10.1 · FINANCIAL MODEL — IRR SCENARIOS Page 82

10.1

Base-case IRR reaches 22% only above 6,000 tonne annual output

At 6,000 tonnes and an 8% domestic price premium over China CIF, the model produces a 22% IRR and 6.4-year payback. IRR falls to 11% at import price parity — below cost of capital at any scale under 5,200 tonnes.

Downside Case

11%

IRR

Payback9.1 yrs

Price premium0%

Output6,000T

Import price parity. Investment does not exceed cost of capital.

Base Case ✦ Target
22%
IRR
Payback6.4 yrs
Price premium8%
Output6,000T
8% domestic premium sustained. Viable but not robust — premium is the controlling variable.

Upside Case

31%

IRR

Payback4.8 yrs

Price premium15%

Output6,000T

Triggered by tariff event or supply disruption. Dependent on premium holding through investment horizon.

75% China import share — structural dependency

7,500T annual market volume, pharmaceutical-grade

22mo CDSCO critical path — greenfield timeline

INR
280Cr minimum viable capital requirement

22% base-case IRR at 6,000 tonne output

42% of production cost attributable to power

The research. Before the engagement starts.

caspr.ai · Your first $100 on Caspr